Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett speaks with Proactive about the activation of the first Australian clinical site for the RC220 Phase I solid tumour trial. Dr Tillett confirms that the trial is now underway and open to patient enrolment.

Watch the full interview below. Additional report can be found here.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@raceoncology.com T: +61 2 8051 3043
© 2025 Race Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Race Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.